Jeff Yass’s NewAmsterdam Pharma NAMS Stock Holding History

Jeff Yass’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.6M	Buy	754,327 +736,502	+4,132%	+$24.3M	﹤0.01%	2190
2026 Q1	$571K	Sell	17,825 -177,810	-91%	-$5.79M	﹤0.01%	9326
2025 Q4	$6.86M	Buy	195,635 +43,798	+29%	+$1.59M	﹤0.01%	3560
2025 Q3	$4.32M	Buy	151,837 +62,010	+69%	+$1.49M	﹤0.01%	4326
2025 Q2	$1.63M	Sell	89,827 -59,209	-40%	-$1.08M	﹤0.01%	6236
2025 Q1	$3.05M	Buy	149,036 +140,070	+1,562%	+$3.11M	﹤0.01%	4611
2024 Q4	$230K	Buy	+8,966	New	+$190K	﹤0.01%	10400

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Jeff Yass's NAMS Position: Q2 2026 in Review

Jeff Yass increased its NewAmsterdam Pharma (NAMS) stake by 4,132% in Q2 2026, buying an estimated $24.3M and bringing the position to 754,327 shares worth $25.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

Jeff Yass first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Jeff Yass held 754,327 shares of NewAmsterdam Pharma worth $25.6M as of Q2 2026.
Jeff Yass bought 736,502 NewAmsterdam Pharma shares in Q2 2026, an estimated $24.3M.
NewAmsterdam Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2190 holding.
Jeff Yass first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.